抗瘤增效方联合替吉奥治疗晚期结直肠癌疗效及对患者生存质量、血清肿瘤标志物的影响

Efficacy of Anti-tumor Synergistic Formula Combined with Tegafur on Advanced Colorectal Cancer and Effect on Quality of Life and Serum Tumor Markers

目的:观察抗瘤增效方联合替吉奥治疗晚期结直肠癌疗效及对生存质量、血清肿瘤标志物的影响,并探讨其作用机制。方法:选取2013年1月至2015年12月确诊的100例晚期结直肠癌(advanced colorectal cancer,ACC)患者,随机分成两组,每组50例。对照组予替吉奥胶囊治疗,研究组在上述基础上予抗瘤增效方治疗。检测外周血T淋巴细胞和相关肿瘤标志物,评估生活质量,随访并记录各自生存时间,比较治疗效果和生存率。结果:与治疗前比较,对照组CD3^+,CD4^+,CD4^+/CD8^+降低(P<0.01),CD8^+升高(P<0.01);研究组CD3^+,CD4^+,CD4^+/CD8^+升高(P<0.01),CD8^+降低(P<0.01);两组癌胚抗原(carcinoembryonic antigen,CEA),肿瘤相关黏液抗原(carbohydrate antigen 242,CA242),糖链抗原19-9(carbohydrate antigen 19-9,CA19-9)均显著降低(P<0.01),生活质量核心量表(Quality of Life Questionnaire-Core 30,QLQ-C30)功能领域评分升高(P<0.01),QLQ-C30症状领域评分降低(P<0.01);治疗后与对照组比较,研究组CD3^+,CD4^+,CD4^+/CD8^+较高(P<0.01),CD8^+较低(P<0.01),CEA,CA242,CA19-9较低(P<0.01);QLQ-C30功能领域评分较高(P<0.01),QLQ-C30症状领域评分较低(P<0.01),客观缓解率(objective response rate,ORR)较高(P<0.05),随访生存率较高(P<0.05)。结论:抗瘤增效方联合替吉奥能提高ACC生存质量和生存率,治疗效果较理想,值得借鉴。

Objective ： To investigate the efficacy of anti-tumor synergistic formula combined with tegafur on advanced colorectal cancer and the effect on quality of life and serum tumor markers, and explore their mechanism of action. Method ： A total of 100 advanced colorectal cancer （ACC） patients diagnosed at our hospital between January 2013 and December 2015 were selected and randomly divided into two groups, with 50 cases in each group. The control group was treated with Gimeracil and Oteracil Porassium capsules, and the experiment group was treated with anti-tumor synergistic formula in addition to the therapy of control group. Peripheral blood T lymphocytes and related tumor markers were detected, the quality of life was assessed, and follow-up visits were made to record their respective survival time and compare the treatment effect and survival rate. Result： Compared with before treatment, CD3 ~ , CD4 ＋ and CD4 ＋/CD8 ＋ levels were lower （P 〈 0.01 ） , and the CD8 ＋ level was higher （P 〈0.01） in control group, and the CD3 ＋ , CD4＋ and CD4~/CD8 ＋levels were higher （P 〈0.01 ）, and the CD8 ＋ level was lower （ P 〈 0.01 ） in experiment group. Carcinoembryonic antigen （CEA） , carbohydrate antigen 242 （CA242） and carbohydrate antigen 19-9 （CA19-9） levels were lower in two groups （P 〈 0.01 ）, the Quality of Life Questionnaire-Core 30 （QLQ-C30） scale function domain score was increased （P 〈 0.01 ）, and the QLQ-C30 symptom domain score was lower （P 〈 0.01 ）. Compared with control group, the CD3＋ , CD4＋ and CD4＋/CD8＋levels were higher （P 〈0.01）, the CEA, CA242 and CA19-9 levels were lower （P 〈 0.01 ）, the QLQ-C30 scale function domain score was increased （P 〈 0.01 ） , and the QLQ-C30 symptom domain score was lower （P 〈 0.01 ） , the objective response rate （ORR） was higher （P 〈 0.05 ） , and the follow-up survival rate was higher （P 〈 0.05） in experiment group. Conclusion： Anti-tumor synergistic formula combined with tegafur can improve the quality of life and survival of ACC, shows an ideal treatment effect, and is worth promotion.